A. Camez

1.2k total citations · 1 hit paper
24 papers, 902 citations indexed

About

A. Camez is a scholar working on Surgery, Internal Medicine and Genetics. According to data from OpenAlex, A. Camez has authored 24 papers receiving a total of 902 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 8 papers in Internal Medicine and 8 papers in Genetics. Recurrent topics in A. Camez's work include Inflammatory Bowel Disease (8 papers), Venous Thromboembolism Diagnosis and Management (8 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (6 papers). A. Camez is often cited by papers focused on Inflammatory Bowel Disease (8 papers), Venous Thromboembolism Diagnosis and Management (8 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (6 papers). A. Camez collaborates with scholars based in France, United States and Germany. A. Camez's co-authors include J.‐H. Saurat, Kim Papp, J.‐P. Ortonne, Martin Kaul, Louis Dubertret, Kristina Unnebrink, G Stingl, Richard G. Langley, J.‐P. Ortonne and Dennis A. Revicki and has published in prestigious journals such as Gut, Journal of the American Society of Nephrology and Annals of the Rheumatic Diseases.

In The Last Decade

A. Camez

22 papers receiving 872 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)

2007 559 citations J.‐H. Saurat, G Stingl et al. British Journal of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Camez France	8	630	387	158	153	143	24	902
Nima Melzer Germany	9	267 0.4×	133 0.3×	72 0.5×	56 0.4×	54 0.4×	24	519
Francesca Bartoli Italy	15	271 0.4×	191 0.5×	317 2.0×	78 0.5×	118 0.8×	44	858
Bogdan Batko Poland	15	202 0.3×	24 0.1×	266 1.7×	48 0.3×	75 0.5×	63	528
René Cordtz Denmark	15	200 0.3×	42 0.1×	470 3.0×	156 1.0×	145 1.0×	48	763
Gabor Major Australia	14	200 0.3×	44 0.1×	408 2.6×	286 1.9×	140 1.0×	41	907
Payal M. Patel United States	11	44 0.1×	73 0.2×	92 0.6×	129 0.8×	67 0.5×	36	673
İsmail Şimşek Türkiye	15	91 0.1×	15 0.0×	258 1.6×	96 0.6×	111 0.8×	49	677
Monique Hoekstra Netherlands	11	134 0.2×	23 0.1×	678 4.3×	106 0.7×	269 1.9×	21	939
Javed Sheikh United States	18	352 0.6×	159 0.4×	1.2k 7.3×	454 3.0×	53 0.4×	35	1.7k
Andrei Braester Israel	13	163 0.3×	14 0.0×	30 0.2×	58 0.4×	84 0.6×	63	625

Countries citing papers authored by A. Camez

Since Specialization

Citations

This map shows the geographic impact of A. Camez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Camez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Camez more than expected).

Fields of papers citing papers by A. Camez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Camez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Camez. The network helps show where A. Camez may publish in the future.

Co-authorship network of co-authors of A. Camez

This figure shows the co-authorship network connecting the top 25 collaborators of A. Camez. A scholar is included among the top collaborators of A. Camez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Camez. A. Camez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ammari, Samy, A. Camez, Yasmina Chaibi, et al.. (2024). Contribution of an Artificial Intelligence Tool in the Detection of Incidental Pulmonary Embolism on Oncology Assessment Scans. Life. 14(11). 1347–1347. 2 indexed citations

Jaffe, Glenn J., Jennifer E. Thorne, David K. Scales, et al.. (2015). SAT0523 Adalimumab in Patients with Active, Non-Infectious Uveitis Requiring High-Dose Corticosteroids: the Visual-1 Trial. Annals of the Rheumatic Diseases. 74. 849–850. 6 indexed citations

Panaccione, Remo, Édouard Louis, Ming‐Chin Yang, et al.. (2013). P163 Quality of life for patients with deep remission vs. clinical remission and deep remission vs. absence of mucosal ulceration: 3-year data from CHARM/ADHERE. Journal of Crohn s and Colitis. 7. S74–S74. 1 indexed citations

Sandborn, W., Remo Panaccione, E Louis, et al.. (2012). P257 Importance of deep remission compared with mucosal healing only: Results from EXTEND. Journal of Crohn s and Colitis. 6. S112–S112. 2 indexed citations

Sandborn, W., J F Colombel, Kathleen G. Lomax, et al.. (2011). Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with crohn's disease: data from extend: Table 1. Gut. 60(Suppl 1). A136.2–A137. 10 indexed citations

Sandborn, William J., J F Colombel, P. Rutgeerts, et al.. (2011). Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease. Inflammatory Bowel Diseases. 17(suppl_1). S60–S60. 1 indexed citations

Colombel, J F, Stefan Schreiber, P. Rutgeerts, et al.. (2011). Effect of disease duration on ‘deep remission’. Inflammatory Bowel Diseases. 17(suppl_1). S44–S44. 1 indexed citations

Louis, Édouard, Robert Löfberg, Walter Reinisch, et al.. (2009). P118 - Adalimumab's effect on extraintestinal manifestations of Crohn's disease: results of the CARE trial. Journal of Crohn s and Colitis. 3(1). S57–S58.

Reinisch, Walter, Robert Löfberg, Erik K. St. Louis, et al.. (2009). P125 - Influence of disease duration on adalimumab efficacy in Crohn's disease: subanalysis of the CARE trial. Journal of Crohn s and Colitis. 3(1). S60–S60. 2 indexed citations

10.

Revicki, Dennis A., Mary Kaye Willian, J.‐H. Saurat, et al.. (2007). Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. British Journal of Dermatology. 158(3). 549–557. 137 indexed citations

11.

Saurat, J.‐H., G Stingl, Louis Dubertret, et al.. (2007). Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). British Journal of Dermatology. 158(3). 558–566. 559 indexed citations breakdown →

12.

Vanholder, Raymond, A. Camez, Nic Veys, et al.. (1997). Pharmacokinetics of Recombinant Hirudin in Hemodialyzed End-stage Renal Failure Patients. Thrombosis and Haemostasis. 77(4). 650–655. 81 indexed citations

13.

Bridey, Françoise, Marie Dreyfus, Florence Parent, et al.. (1995). Recombinant hirudin (HBW 023): Biological data of ten patients with severe venous thrombo‐embolism. American Journal of Hematology. 49(1). 67–72. 11 indexed citations

14.

Schiele, François, et al.. (1995). [Subcutaneous recombinant hirudin in the treatment of deep venous thrombosis. A pharmacokinetic study].. PubMed. 88(3). 329–35.

15.

Schiele, François, Alain Vuillemenot, J Soria, et al.. (1994). A Pilot Study of Subcutaneous Recombinant Hirudin (HBW 023) in the Treatment of Deep Vein Thrombosis. Thrombosis and Haemostasis. 71(5). 558–562. 35 indexed citations

16.

Vanholder, Raymond, A. Camez, Nic Veys, & S Ringoir. (1993). Hirudin A specific thrombin inhibitor as anticoagulant for hemodialysis. Journal of the American Society of Nephrology. 4(3). 393. 5 indexed citations

17.

Siè, Piérre, et al.. (1991). Locally activated coagulation induced by a peripheral endovenous catheter. Thrombosis Research. 64(6). 775–782. 1 indexed citations

18.

Tobelem, G, R Cariou, & A. Camez. (1987). The lupus anticoagulant and its role in thrombosis. Blood Reviews. 1(1). 21–24. 23 indexed citations

19.

Camez, A., G Tobelem, Sylvia Bellucci, et al.. (1986). [Course of the manifestations associated with the antiprothrombinase circulating anticoagulant].. PubMed. 15(11). 515–8. 1 indexed citations

20.

Camez, A., Évelyne Dupuy, Sylvia Bellucci, et al.. (1986). Human platelet-tumor cell interactions vary with the tumor cell lines.. PubMed. 6(6). 321–34. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact